Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Jeffrey Seow,
Zayed A. Shalim,
Carl Graham,
Simon Kimuda,
Aswin Pillai,
Thomas Lechmere,
Ashwini Kurshan,
Atika M. Khimji,
Luke B. Snell,
Gaia Nebbia,
Christine Mant,
Anele Waters,
Julie Fox,
Michael H. Malim,
Katie J. Doores
Affiliations
Jeffrey Seow
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Zayed A. Shalim
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Carl Graham
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Simon Kimuda
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Aswin Pillai
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Thomas Lechmere
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Ashwini Kurshan
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Atika M. Khimji
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Luke B. Snell
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Gaia Nebbia
Department of Infectious Diseases, Centre for Clinical Infection and Diagnostics Research, Guy’s and St Thomas’ NHS Foundation Trust , London, United Kingdom
Christine Mant
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Anele Waters
Harrison Wing, Guy's and St Thomas’ NHS Foundation Trust , London, United Kingdom
Julie Fox
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Michael H. Malim
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
Katie J. Doores
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London , London, United Kingdom
ABSTRACT Despite the success of COVID-19 vaccines in preventing infection and/or severe disease, there has been an increase in SARS-CoV-2 infections in vaccinated individuals owing to the waning vaccine-derived immunity, and the emergence of new variants which encode escape mutations in Spike. Following breakthrough infection in vaccinated individuals, an increase in neutralization breadth has been observed in sera/plasma. However, how exposure to a heterologous Spike broadens the neutralizing response at the monoclonal antibody (mAb) level is not fully understood. Through isolation of 119 mAbs from three individuals receiving two doses of BNT162b2 vaccine before becoming Delta or Omicron/BA.1 infected, we show that serum breadth occurs due to the presence of somatically mutated mAbs with broad neutralization activity indicative of re-activation and maturation of B cells generated through previous COVID-19 vaccination. Isolated mAbs frequently show reduced neutralization of current circulating variants including BA.2.75.2, XBB, XBB.1.5, and BQ.1.1 confirming continuous selective pressure on Spike to evolve and evade neutralization. However, isolation of mAbs that display effective cross-neutralization against all variants indicates the presence of conserved epitopes on the receptor binding domain and a lesser extent the N-terminal domain. These findings have implications for the selection of Spike antigens for next-generation COVID-19 vaccines. IMPORTANCE With the emergence of SARS-CoV-2 viral variants, there has been an increase in infections in vaccinated individuals. Here, we isolated monoclonal antibodies (mAbs) from individuals experiencing a breakthrough infection (Delta or BA.1) to determine how exposure to a heterologous Spike broadens the neutralizing antibody response at the monoclonal level. All mAbs isolated had reactivity to the Spike of the vaccine and infection variant. While many mAbs showed reduced neutralization of current circulating variants, we identified mAbs with broad and potent neutralization of BA.2.75.2, XBB, XBB.1.5, and BQ.1.1 indicating the presence of conserved epitopes on Spike. These results indicate that variant-based vaccine boosters have the potential to broaden the vaccine response.